A Phase II, Randomized, Parallel-Group, Double-Blind, Double-Dummy, Placebo-Controlled, Multicenter Study To Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and Compared With Vedolizumab in Patients With Moderate to Severe Ulcerative Colitis
Phase of Trial: Phase II
Latest Information Update: 20 Nov 2019
Price : $35 *
At a glance
- Drugs RG 7880 (Primary) ; Vedolizumab
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors Genentech
- 05 Sep 2019 This trial has been discontinued in Netherlands.
- 18 Jul 2019 Planned End Date changed from 24 Sep 2021 to 12 Jan 2022.
- 18 Jul 2019 Planned primary completion date changed from 23 Apr 2021 to 11 Aug 2021.